Nicox Presents Phase 2 Results on NCX 4251 and New Nonclinical Evidence of Improved Hemodynamic and Retinal Cell Physiology on NCX 470
Nicox SA announced poster presentations highlighting the effect of NCX 4251 in patients with dry eye disease as well as new nonclinical evidence of neuroprotective activity on NCX 470 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 annual meeting, one of the key scientific events in vision research, being held in person on May 1-4, 2022 in Denver, Colorado, United States and virtually on May 11-12.
Details of the poster presentations (all U.S. local times):
Title: Eyelid application of NCX 4251 for treatment of signs and symptoms of dry eye disease
Session title: Dry Eye, Clinical
Date: May 2, 2022 from 12:30 PM to 2:30 PM MDT
Presentation number: 1542 – A0267
Presenter: Gary Foulks MD, Emeritus Professor, University of Louisville Department of Ophthalmology and Vision Sciences, Louisville, KY, United States.
NCX 4251 is a novel and patented ophthalmic suspension of fluticasone propionate nanocrystals currently in phase 2 development in the US for patients with dry eye disease.
Title: NCX 470, a nitric oxide (NO)-donating prostaglandin analog, restores ocular hemodynamic and photoreceptor function after endothelin-1-induced ischemia/reperfusion injury in rabbits
Session title: Neuroprotection and Neuroregeneration
Date: May 2, 2022 from 12:30 PM to 2:30 PM MDT
Presentation number: 1606 – A0429
Presenter: Francesco Impagnatiello, PhD, Nicox Research Institute, Milan Italy
Title: NCX 470, a nitric oxide (NO)-donating prostaglandin analog, elicits sustained IOP-lowering and modifies aqueous humor dynamic in non-human primates
Session Title: Pharmacology/cellular Mechanisms
Date: May 3, 2022 from 1:00 PM to 3:00 PM MDT
Presentation number: 2839 – A0362
Presenter: Elena Bastia, PhD, Nicox Research Institute, Milan, Italy
Nicox’s lead product candidate, NCX 470, is a novel nitric oxide (NO) donating prostaglandin analog being studied in two multi-regional phase 3 clinical trials, Mont Blanc and Denali, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.